Get the Daily Brief
Latest Biotech News
Eclipsebio buys Terrain Bio: RNA design meets sequencing analytics
Eclipsebio acquired Terrain Bio to accelerate an end‑to‑end RNA therapeutic platform that couples machine‑learning RNA design with deep sequencing analytics. Eclipsebio said the acquisition will...
iXCells and Rosebud pair up on organoids... rare disease models scaled
iXCells Biotechnologies and Rosebud Biosciences announced a partnership to combine iXCells’ scalable iPSC platform (iPSCore) with Rosebud’s AI‑driven organoid generation to produce complex 3D...
AI‑designed anti‑CRISPRs: de novo proteins switch off Cas13 fast
An academic team used AI‑accelerated protein design to generate new anti‑CRISPR proteins (AIcrs) that inhibit Cas13a, producing functional inhibitors in bacterial and human cells within eight...
In vivo CAR‑T reduces liver fibrosis: stellate cell targeting shows reversal
Mount Sinai researchers reported an in vivo CAR‑T approach that selectively targets fibroblast activation protein alpha (FAP)‑expressing stellate cells and reduced liver fibrosis in models of...
FDA lifts hold on Intellia CRISPR trial – one Phase 3 resumes after liver event
The U.S. Food and Drug Administration has lifted a clinical hold on Intellia Therapeutics’ Magnitude-2 Phase 3 trial of its CRISPR/Cas9 therapy nexiguran ziclumeran (nex‑z) for transthyretin...
FDA clears Life Biosciences reprogramming study – first human test of age‑rewind approach
The U.S. FDA has approved Life Biosciences’ first-in-human trial of a cell reprogramming gene therapy intended to reverse aspects of cellular aging. The initial study will test ER‑100 in patients...
Roche’s GLP‑1/GIP CT‑388 posts weight‑loss signal — company pushes to Phase 3
Roche announced Phase 2 results for CT‑388 showing a placebo‑adjusted weight loss of about 22.5% at 48 weeks (22.5% excluding discontinuations; ~18.3% when counting dropouts), and said it will...
Eclipsebio buys Terrain Bio – AI design meets sequencing analytics for RNA drugs
Eclipsebio has acquired Terrain Bio to accelerate an integrated platform for RNA therapeutic design, manufacturing and validation. The deal combines Terrain’s machine‑learning RNA analytics with...
Parse and Graph partner to build immune perturbation atlas – scale and context for AI drug discovery
Parse Biosciences and Graph Therapeutics announced a strategic collaboration to create a large, functional immune perturbation atlas profiling hundreds of millions of human cells. The program will...
Insilico inks $120M pact with Qilu — AI‑powered cardiometabolic discovery deal
Insilico Medicine signed a collaboration with Shanghai’s Qilu Pharmaceutical worth up to $120 million to discover small molecules for cardiometabolic diseases using Insilico’s AI drug‑discovery...
Altido Bio raises seed to commercialize MGH CAR‑T for glioblastoma – early tumor shrinkage seen
Altido Bio closed a $12.5 million seed round led by ARCH Venture Partners to advance a CAR‑T therapy developed at Massachusetts General Hospital for glioblastoma. The startup, led by industry...
TRexBio extends Series B with $50M — funds Treg‑activating programs into the clinic
TRexBio secured an additional $50 million in a Series B extension to advance TRB‑061 and other Treg‑focused programs toward human testing. The financing will support Phase 1 work in atopic...
10x Genomics pushes into clinical diagnostics – CLIA lab, hospital partnerships in motion
10x Genomics announced clinical collaborations with Brigham & Women’s Hospital, Dana‑Farber Cancer Institute and the Cancer Research Institute and committed to build a CLIA‑certified laboratory to...
Oxford Nanopore reverses P2 Solo sunset – support extended to 2030 after backlash
Oxford Nanopore Technologies extended support for its PromethIon 2 Solo (P2 Solo) sequencer through the end of 2030 after strong customer criticism of an earlier discontinuation plan. The company...
CMS Adds 15 Drugs for IRA Price Talks — $27B at Stake
The Centers for Medicare & Medicaid Services on Jan. 27 identified 15 high-spend medicines for the next round of price negotiations under the Inflation Reduction Act. The list includes inhalers,...
FDA Greenlights Reprogramming Trial: Life Biosciences to Test ER‑100
The FDA has allowed Life Biosciences to begin the first human study of an epigenetic “reprogramming” gene therapy, enrolling a small cohort of glaucoma patients under the ER‑100 program. The trial...
Roche Pushes CT‑388 to Phase 3 — 22.5% Placebo‑Adjusted Weight Loss
Roche reported mid‑stage results for CT‑388, a dual GLP‑1/GIP receptor agonist, showing about 22.5% placebo‑adjusted weight loss at 48 weeks in a ~469‑patient Phase 2 study and signaled plans to...
FDA Lifts Hold on One Intellia CRISPR Trial — Cardiac Study Remains Paused
Regulators lifted the clinical hold on Intellia’s Magnitude‑2 Phase 3 trial of its CRISPR/Cas9 therapy for transthyretin amyloidosis with polyneuropathy (ATTR‑PN) while the sibling Magnitude study...
Oxford Nanopore Reverses Course — P2 Solo Supported Through 2030
Oxford Nanopore extended hardware and software support for its PromethIon 2 Solo (P2 Solo) sequencer through the end of 2030 after widespread customer backlash to an earlier phase‑out plan. The...
nRichDx and Hamilton Automate Liquid‑Biopsy Workflow — Wash & Elute Now Integrated
nRichDx and Hamilton advanced a commercial automation partnership to complete the Revolution Plus sample‑prep workflow for liquid biopsy on the Hamilton Microlab STAR platform, integrating the...